JO
NVNO

John Overdeck’s enVVeno Medical NVNO Stock Holding History

John Overdeck’s Portfolio NVNO Stock Details NVNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,561
Closed -$51.2K – 4818
2025
Q4 		$51.2K Buy
+4,561
New +$88.6K ﹤0.01% 3935
2022
Q2 		– Sell
-953
Closed -$213K – 2809
2022
Q1 		$213K Sell
953
-970
-50% -$188K ﹤0.01% 2323
2021
Q4 		$444K Buy
+1,923
New +$542K ﹤0.01% 3366

Other funds holding NVNO

KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

John Overdeck's NVNO Position: Q1 2026 in Review

John Overdeck sold out of enVVeno Medical (NVNO) in Q1 2026, closing a stake of 4,561 shares — an estimated $51.2K sold.

John Overdeck first reported a position in NVNO in Q4 2021 and held it in 3 quarters. The position peaked at $444K in Q4 2021. 17 funds tracked by Wall St. Rank hold NVNO as of Q1 2026.

  • John Overdeck reported no remaining enVVeno Medical position as of Q1 2026 after selling out during the quarter.
  • John Overdeck sold 4,561 enVVeno Medical shares in Q1 2026, an estimated $51.2K.
  • John Overdeck first reported a position in enVVeno Medical in Q4 2021 and held it in 3 quarters.
  • John Overdeck's enVVeno Medical position peaked at $444K in Q4 2021.
  • 17 funds tracked by Wall St. Rank held enVVeno Medical as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.